

AMENDMENTS TO CLAIMS

1-7. (Canceled)

8. (Currently Amended) A method of treating muscle hyperactivity, comprising administering a purified botulinum neurotoxin that is free from a non-toxic protein of the botulinum toxin, to a patient with muscle hyperactivity.

9. (Previously Presented) The method of treatment according to claim 8, wherein the muscle hyperactivity is a disease that needs treatment with a fast acting remedy.

10. (New) The method of treatment according to claim 8, wherein the the purified botulinum neurotoxin is administered in a composition that also comprises a botulinum neurotoxin-stabilizing substance other than the non-toxic protein of the botulinum toxin.

11. (New) The method of treatment according to claim 10, wherein the botulinum neurotoxin-stabilizing substance is human serum albumin.

12. (New) The method of treatment according to claim 8, wherein the botulinum neurotoxin is derived from botulinum toxin type A, B, C, D, E, or F.

13. (New) The method of treatment according to claim 8, wherein the muscle hyperactivity is dystonia.

14. (New) The method of treatment according to claim 9, wherein the administering is conducted while the dosage is adjusted until the effective dose is determined.

15. (New) The method of treatment according to claim 9, wherein the muscle hyperactivity is systemic muscle hyperactivity.

16. (New) The method of treatment according to claim 15, wherein the systemic muscle hyperactivity is generalized dystonia or systemic spasticity.